Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Cardiac amyloidosis, encompassing both transthyretin (ATTR) and light-chain (AL) types, poses considerable challenges in patient management due to its intricate pathophysiology and progressive course. This narrative review elucidates the pivotal role of cardiopulmonary exercise testing (CPET) in the assessment of these patients. CPET is essential for evaluating disease progression by measuring cardio-respiratory performance and providing prognostic insights. This functional test is crucial not only for tracking the disease trajectory, but also for assessing the effectiveness of disease-modifying therapies. Moreover, CPET facilitates the customization of therapeutic strategies based on individual patient performance, enhancing personalized care. By objectively measuring parameters such as peak oxygen uptake (VO2 peak), ventilatory efficiency, and exercise capacity, clinicians can gain a deeper understanding of the degree of functional impairment and make informed decisions regarding treatment initiation, adjustment, and anticipated outcomes. This review emphasizes the importance of CPET in advancing personalized medicine approaches, ultimately striving to improve the quality of life and clinical outcomes for patients with cardiac amyloidosis.

Details

Title
Advancing Cardiac Amyloidosis Care Through Insights from Cardiopulmonary Exercise Testing
Author
Pugliatti, Pietro 1   VIAFID ORCID Logo  ; Trimarchi, Giancarlo 2   VIAFID ORCID Logo  ; Barocelli, Federico 3   VIAFID ORCID Logo  ; Pizzino, Fausto 4   VIAFID ORCID Logo  ; Francesco Di Spigno 5   VIAFID ORCID Logo  ; Tedeschi, Andrea 5   VIAFID ORCID Logo  ; Piccione, Maurizio Cusmà 1 ; Irrera, Pierangela 1 ; Aschieri, Daniela 5   VIAFID ORCID Logo  ; Niccoli, Giampaolo 6 ; Paradossi, Umberto 4   VIAFID ORCID Logo  ; Gianluca Di Bella 1 

 Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy; [email protected] (P.P.); [email protected] (M.C.P.); [email protected] (P.I.); [email protected] (G.D.B.) 
 Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy; [email protected] (P.P.); [email protected] (M.C.P.); [email protected] (P.I.); [email protected] (G.D.B.); Interdisciplinary Center for Health Sciences, Scuola Superiore Sant’Anna, 56127 Pisa, Italy 
 Cardiology Division, Parma University Hospital, 43126 Parma, Italy; [email protected] (F.B.); [email protected] (G.N.) 
 Fondazione Toscana G. Monasterio, Ospedale del Cuore G, Pasquinucci, 54100 Massa, Italy; [email protected] (F.P.); [email protected] (U.P.) 
 Cardiology Unit of Emergency Department, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy; [email protected] (F.D.S.); [email protected] (A.T.); [email protected] (D.A.) 
 Cardiology Division, Parma University Hospital, 43126 Parma, Italy; [email protected] (F.B.); [email protected] (G.N.); Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy 
First page
7285
Publication year
2024
Publication date
2024
Publisher
MDPI AG
e-ISSN
20770383
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3144191317
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.